Publications by authors named "M Makhmudova"
A new triterpene glycoside, silviridoside, was isolated from the aerial parts of (Caryophyllaceae) using different chromatographic techniques. The structure of silviridoside was comprehensively elucidated as 3-β-D-galacturonopyranosyl-quillaic acid 28--β-D-glucopyranosyl-(1→2)-[α-L-rhamnopyranosyl-(1→3)]-β-D-fucopyranosyl ester by one- and two-dimensional nuclear magnetic resonance (NMR) spectroscopy and high-resolution mass spectrometry (HR-MS). Silviridoside showed promising antioxidant activity in different antioxidant assays such as 2,2-diphenyl-1-picrylhydrazyl (DPPH) (2.
View Article and Find Full Text PDFThe compounds (17,20,22,24,25)-5β,6β:20,24-diep-oxy-4β,25-dihy-droxy-1-oxowith-2-en-26,22-olide and (20,22)-5α,14α,20-Trihy-droxy-1-oxo-6α,7α-ep-oxy-witha-2-enolide were isolated from a chloro-form extract of the aerial parts of L. (Solanaceae). Two products were isolated from the chromatographic separation extract.
View Article and Find Full Text PDFArticle Synopsis
- - The study compared two WHO-recommended treatments for rifampin- or multidrug-resistant tuberculosis: a shorter regimen lasting 9-12 months and a longer individualized regimen of at least 20 months, using data from various observational studies.
- - Results showed that the shorter regimen had a higher overall treatment success rate (80.0% vs. 75.3%) and significantly less patient loss to follow-up, though it had a slightly higher risk of treatment failure or relapse, especially in patients with resistance to certain medications.
- - The findings suggest that while the shorter regimen is more effective in maintaining patient engagement, there is a need for better drug susceptibility testing to ensure appropriate treatment, particularly for those with medication resistance. *
New drugs and shorter treatments for drug-resistant tuberculosis (DR-TB) have become available in recent years and active pharmacovigilance (PV) is recommended by the World Health Organization (WHO) at least during the early phases of implementation, with active drug safety monitoring and management (aDSM) proposed for this. We conducted a literature review of papers reporting on aDSM. Up to 18 April, 2019, results have only been published from one national aDSM programme.
View Article and Find Full Text PDFSetting: Tajikistan is among the 30 countries with the highest multidrug-resistant tuberculosis (MDR-TB) burden.
Objective: To investigate the risk factors for unfavourable treatment outcomes among rifampicin-resistant (RR)/MDR-TB patients.
Design: Retrospective medical chart review of RR/MDR-TB patients enrolled for treatment in 2012-2013.